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The physiological role of amyloid precursor protein (APP) has been extensively
investigated in the rodent hippocampus. Evidence suggests that APP plays a role in
synaptic plasticity, dendritic and spine morphogenesis, neuroprotection and—at the
behavioral level—hippocampus-dependent forms of learning and memory. Intriguingly,
however, studies focusing on the role of APP in synaptic plasticity have reported
diverging results and considerable differences in effect size between the dentate gyrus
(DG) and area CA1 of the mouse hippocampus. We speculated that regional differences
in APP expression could underlie these discrepancies and studied the expression
of APP in both regions using immunostaining, in situ hybridization (ISH), and laser
microdissection (LMD) in combination with quantitative reverse transcription polymerase
chain reaction (RT-qPCR) and western blotting. In sum, our results show that APP is
approximately 1.7-fold higher expressed in pyramidal cells of Ammon’s horn than in
granule cells of the DG. This regional difference in APP expression may explain why loss-
of-function approaches using APP-deficient mice revealed a role for APP in Hebbian
plasticity in area CA1, whereas this could not be shown in the DG of the same APP
mutants.
Keywords: APP, dentate gyrus, CA1, immunostaining, western blotting, laser microdissection, in situ
hybridization, RT-qPCR
INTRODUCTION
Amyloid precursor protein (APP) is an integral membrane protein involved in the pathogenesis
of Alzheimer’s disease (AD). It is processed by proteases and cleaved into several biologically
active fragments (e.g., Turner et al., 2003; Müller and Zheng, 2012; Zhang et al., 2012). Of note,
proteolysis of APP by beta- and gamma-secretases generates the amyloid-ß (Aß) peptide, which
oligomerizes, interferes with synaptic functions, and eventually aggregates into extracellular
amyloid plaques, one of the neuropathological hallmarks of AD (Selkoe and Hardy, 2016). In
contrast, proteolysis of APP by α-secretases (e.g., Postina et al., 2004; Yang et al., 2006; Fahrenholz,
2007; Prinzen et al., 2009; Saftig and Reiss, 2011; Kuhn et al., 2016), generates soluble APP-α
(sAPPα), which is neuroprotective and important for neuronal plasticity (Turner et al., 2003; Ring
et al., 2007; Aydin et al., 2012; Kögel et al., 2012). In the latter case, the Aß-peptide is not formed
because α-secretases cleave APP within the Aß region of the protein. In AD the balance of this
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processing by secretases shifts towards the amyloidogenic
pathway, which increases Aß production and leads to a lack
of sAPPα (Endres and Fahrenholz, 2012) resulting in an
impairment of cognition.
A region of the brain which is of particular interest in
the context of AD is the hippocampus. Since the hippocampal
formation and hippocampus-dependent learning and memory
are affected early during the course of the disease (Braak and
Braak, 1991) the hippocampus has been used as a model brain
region to study the role of APP and its cleavage products in
synaptic plasticity, learning and memory and neuroprotection
(e.g., Turner et al., 2003; Ring et al., 2007). Interestingly, our
physiological investigations of APP−/−mice revealed remarkable
differences between the subregions of the hippocampus: whereas
APP was necessary for long-term potentiation (LTP) at the
CA3–CA1 synapse (Ring et al., 2007; Weyer et al., 2011; Hick
et al., 2015) it was not essential for LTP at the entorhinal
cortex-granule cell (EC-GC) synapse in the dentate gyrus (DG;
Jedlicka et al., 2012). We speculated that regional differences
in basal APP expression or APP processing could explain
these phenotypic differences. This interpretation would be in
line with a recent publication, which reported APP to be
predominantly expressed by interneurons in the DG (Wang et al.,
2014).
To provide first evidence for this hypothesis and to reliably
quantify differences in APP expression between granule cells
of the DG and pyramidal cells of area CA1, we studied layer-
specific expression levels of APP in the principal cell layers using
laser microdissection (LMD) in combination with quantitative
polymerase chain reaction (qPCR) and western blot analysis
(e.g., Burbach et al., 2003; Del Turco et al., 2014). Since APP
is alternatively spliced into three major isoforms (Kang et al.,
1987; Tanzi et al., 1988; Sisodia et al., 1993; Rohan de Silva
et al., 1997), i.e., APP-770, APP-695 and APP-751, assays
detecting all major isoforms were employed. Furthermore, we
used an antibody for western blotting, which is highly specific
for APP and does not show staining on APP−/− brain tissue
(Guo et al., 2012) to quantify APP levels and to study its
cellular distribution. The selection of the antibody appeared to
be especially important, since some antibodies show unspecific
background staining on tissue sections and may cross-react
with APP-related proteins, such as the APP-like-proteins 1 or
2 (Anliker and Müller, 2006; Kaden et al., 2012; Müller and
Zheng, 2012). Together with in situ hybridization (ISH) data
for APP, our results show that APP is expressed exclusively
by hippocampal neurons under physiological conditions. It is
∼1.7 fold higher expressed by CA1 pyramidal cells compared
to dentate granule cells, which may contribute to the regional
differences seen in electrophysiological studies of APP−/− mice
(Ring et al., 2007; Jedlicka et al., 2012).
MATERIALS AND METHODS
Animals
Adult (3–5 months old) male C57BL/6J mice (Janvier, France)
and APP-deficient mice obtained from the colony at Heidelberg
University (e.g., Li et al., 1996; Jedlicka et al., 2012) were used for
experimental analysis. Animal care and experimental procedures
were performed in agreement with the German law on the use
of laboratory animals (animal welfare act; TierSchG). Animal
welfare was supervised and approved by the Institutional Animal
Welfare Officer.
Immunofluorescence
Mice were deeply anesthetized with an overdose of pentobarbital
(300 mg/kg body weight) and transcardially perfused with 0.9%
sodium chloride (NaCl) followed by 4% paraformaldehyde
(PFA) in phosphate-buffered saline (pH 7.4). Brains were
removed, post-fixed for 4–24 h in 4% PFA and sectioned in
the coronal plane (40 µm) using a vibratome (VT1000 S,
Leica Microsystems). Free-floating sections were incubated
in a blocking buffer containing 0.5% Triton X-100 and
5% bovine serum albumin (BSA) in 0.05 M Tris-buffered
saline (TBS) for 30 min at room temperature followed
by incubation in the primary antibody (diluted in 0.1%
Triton X-100 and 1% BSA in 0.05 M TBS) overnight at
4◦C. The following primary antibodies were used: mouse
anti-APP (22C11, immunogen: 66–81 amino acids (aa) of
purified recombinant Alzheimer precursor A4 fusion protein
(N-terminus); MAB348, Chemicon), rabbit anti-APP (CT20,
immunogen: synthetic peptide corresponding to 751–770 aa
of human APP (C-terminus); 171610, Calbiochem), rabbit
anti-APP (Y188, immunogen: synthetic peptide corresponding
to C-terminus of human APP (YENPTY motif); ab32136,
Epitomics), mouse anti-NeuN (A60, immunogen: purified cell
nuclei from mouse brain; MAB377, Chemicon) and rabbit
anti-GFAP (immunogen: GFAP isolated from cow spinal cord;
Z0334, Dako). After several washes, sections were incubated with
the appropriate secondary Alexa-conjugated antibodies (1:2000,
Invitrogen, Waltham, MA USA) for several hours at room
temperature, counterstained with Hoechst 33242 (Invitrogen)
or DRAQ5 (Thermo Fisher Scientific, Waltham, MA, USA),
and finally mounted in DAKO Fluorescent Mounting Medium
(Dako).
Western Blotting
For protein extraction, 10× volume of homogenization buffer
(20 mM Tris, 500 mM NaCl, 0.5% CHAPS, 5 mM EDTA)
was added to freshly dissected tissue samples, i.e., whole
hippocampus as well as microdissected CA1 pyramidal cell
layer (pcl) and dentate granule cell layer (gcl). Homogenization
was performed with a pestle (Wheaton, Montgomery, MD,
USA). After centrifugation at 4◦C for 30 min (22,000 rpm,
Sorvall WX Ultra Series, Thermo Electron Corporation), protein
concentration was quantified with a Qubitr 2.0 Fluorometer
(Life Technologies, Carlsbad, CA, USA) using Qubitr Protein
Assay Kit (Life Technologies, Carlsbad, CA, USA). Samples were
denatured for 5 min at 95◦C and immediately cooled down on
ice. For gel electrophoresis, protein amounts (approx. 30 µg
for hippocampal tissue, 5–6 µg for microdissected tissue) were
loaded onto 8% SDS–polyacrylamide gels and were separated
at 120 V for 15 min followed by 160–180 V for 45 min.
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Subsequently, gels were blotted to nitrocellulose membranes at
15 V for 75 min. Blots were then washed twice in TBS and
incubated with Odyssey Blocking Buffer (LI-COR Biosciences)
at room temperature for 60–120 min. Blots were washed again
in TBS and incubated overnight at 4◦C with the appropriate
primary antibody diluted in 1:1 Odyssey Blocking Buffer with
TBS and 0.1% Tween20. Blots were washed in TBS with
0.1% Tween20 and incubated with an IRDye800CW conjugated
secondary antibody (LI-COR Biosciences) at room temperature
for 45 min. For normalization mouse anti-GAPDH antibody
(Calbiochem) in combination with an IRDye680 conjugated
goat anti-mouse antibody (LI-COR Biosciences) was used.
Two-color imaging was performed using Odysseyr Infrared
Imaging System (LI-COR Biosciences). Densitometric analysis
for each protein band was done using the Image Studio Software
(LI-COR Biosciences). Each protein quantification was first
normalized against GAPDH (loading control) from the same
gel (intra-blot analysis), before comparisons for changes were
made (inter-blot comparisons). The results (x-fold) are presented
as means and standard deviations (SD) of three independent
experiments. Statistics were analyzed using Student’s t-test. P
values of ≤ 0.05 were considered statistically significant.
In situ Hybridization
An ISH probe specific for all major App isoforms was designed
to detect the juxtamembrane region of APP. To this end, a
cDNA fragment encoding aa 492–623 of APP695 was cloned
into the pcDNA3 vector. Prior to in vitro transcription,
the plasmid was linearized and gel-purified using a gel
extraction kit (Qiagen). in vitro transcription of DIG-labeled
antisense RNA probe from the SP6 promoter was performed
using the Roche DIG RNA labeling kit (SP6/T7), following
the manufacturer’s instructions. Probes were subsequently
purified using RNase-free ChromaSpin 100 columns (Clontech).
The quantity of labeled and purified probe was estimated
by Dot blot as described in the DIG RNA labeling kit
manual.
Whole mouse brains were dissected and immediately placed
on dry ice until they were thoroughly frozen. Brain slices
(14 µm) were cut on a cryostat (Zeiss Hyrax C50), collected
on Superfrost plus slides (Thermo Scientific) and dried at 56◦C
for 30 min. Sections were fixed for 10 min in 4% PFA in
PBS, washed thrice in diethyl pyrocarbonate (DEPC)—treated
PBS, and then permeabilized and acidified in triethanolamine
hydrochloride (TEA-HCl)—acetic anhydride for 10 min. After
three washing steps with DEPC-PBS, slices were dehydrated
in an ethanol series (50%, 75%, 95%, 100%; 5 min each) and
dried for at least 2 h at 56◦C. Anti-sense probe was diluted
in hybridization buffer to the final concentration of approx.
400 pg/µl and heated to 80◦C for 10 min. After cooling down
on ice, 100 µl of hybridization solution were applied to each
slide, which was then covered with parafilm. Hybridization was
done overnight at 56◦C. On the next day, slides were placed
in 4× SSC for 10 min to wash off excess probe. Stringent
washing steps were 30 min in 0.2× SSC at 60◦C, followed
by another 90 min in fresh 0.2× SSC at 60◦C, followed
by 10 min in 0.2× SSC at room temperature. For probe
detection, slides were equilibrated in P1DIG (100 mM Tris-
HCl; 150 mM NaCl) for 10 min and blocked in blocking
solution (P1DIG + 0.5% BSA + 1% Blocking reagent, Roche)
for 30 min. Brain slices were encircled with PAP PEN and anti-
DIG-AP antibody (80 µl, diluted 1:500 in blocking solution)
was pipetted on every brain slice. Antibody incubation was
done overnight at 4◦C in a humidified chamber. The next
day, all slides were washed twice for 15 min in P1DIG, then
equilibrated in P3DIG (100mMTris-HCl; 100mMNaCl; 50mM
MgCl2, pH 9.5) for 2 min. Slides were incubated in substrate
solution (NBT/BCIP, diluted 1:50 in P3DIG) overnight at room
temperature until color development was sufficient. Slides were
then washed in PBS, fixed for 10 min in 4% PFA in PBS,
washed in P4DIG (10 mM Tris-HCl; 1 mM EDTA, pH 8.0) for
10 min, then air dried for 2 h and finally mounted in Mowiol
(Polysciences).
Digital Illustrations
Figures were prepared digitally using commercially available
graphics software (Photoshop, Adobe Inc., San Jose, CA,
USA). Fluorescent images were acquired using a digital camera
(Digital Sight DS-M5c, Nikon, Germany) or confocal microscopy
(Eclipse C1 Plus, Nikon). Single fluorescent images of the same
section were digitally superimposed. The contrast, brightness and
sharpness of images were adjusted as needed for each section. No
additional image alteration was performed.
Laser Microdissection
Mice were killed by an overdose of isoflurane (Abbott).
Brains were rapidly removed from the cranium, embedded in
tissue freezing medium and immediately flash-frozen in −70◦C
isopentane cooled by dry ice. Cryostat sections (8 µm for
RNA analysis, 20 µm for western blotting) were mounted on
polyethylene naphthalene (PEN) or polyester (POL) slides (Leica
Microsystems). For RNA analysis, sections were fixed shortly
in −20◦C cold acetone, stained with 1% cresyl violet staining
solution and dehydrated in 75% and 100% ethanol. Using a Leica
LMD6500 system (Leica Microsystems), defined tissue samples
of the dentate gcl and of CA1 pcl were collected separately from
the same brain sections and transferred to −80◦C until further
processing.
RNA Isolation and Reverse Transcription
Total RNA was isolated using the RNeasy Plus Micro Kit
(Qiagen) according to the manufacturer’s recommendations.
RNA integrity was assessed using the Agilent 2100 Bioanalyzer
system and Agilent RNA 6000 Pico Kit (Agilent Technologies),
and then reverse transcribed using High Capacity cDNA Reverse
Transcription Reagents Kit (Applied Biosystems) following the
manufacturer’s recommendations.
Quantitative Polymerase Chain Reaction
(qPCR)
cDNAwas amplified using TaqManr Fast Universal PCRMaster
Mix (Applied Biosystems) and the StepOnePlus Real-Time
PCR System (Applied Biosystems). PCR products were checked
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on Agilent DNA 1000 Chips (Agilent Technologies) with the
Agilent 2100 Bioanalyzer system to verify product specificity
and amplicon size. Quantification of the gene expression
of candidate reference genes was carried out using SYBRr
GreenERTM qPCR Supermix Universal (Invitrogen, Waltham,
MA, USA) following the manufacturer’s recommendations.
Primer efficiencies and quantification cycle (Cq) values were
calculated using LinRegPCR Software (Tuomi et al., 2010). To
determine the most stable reference genes and the minimum
number for accurate normalization, NormFinder (Andersen
et al., 2004) and geNorm (Vandesompele et al., 2002) were used
according to the developer’s manuals. qPCR data were tested
for statistical significance using one-way ANOVA followed by
Bonferroni post hoc test to correct for multiple comparisons,
∗p ≤ 0.05.
RESULTS
APP is Differentially Expressed in the
Principal Cell Layers of the Hippocampus
For immunohistochemical detection of APP protein in the adult
mouse hippocampus, widely used antibodies against APP were
selected which recognize themajor isoforms of APP in the rodent
brain, i.e., APP-770, APP-695 and APP-751. To address the
specificity of these antibodies, we tested the antibodies on wild
type (APP+/+) andAPP deficient (APP−/−) brain tissue sections.
Two of the antibodies, i.e., Y188 and CT20, that both recognize
C-terminal APP epitopes showed immunoreactivity only in
APP+/+ brain sections but virtually no staining in APP−/−
hippocampal tissue (Figures 1A–J). Using these antibodies, a
considerably stronger fluorescence signal was observed in the
principal layers of the Ammon’s horn compared to the dentate
gcl (Figures 1A,B,D,F,G,I). Non-specific immunoreactivity was
moderately higher in APP−/− sections using CT20 compared
to the Y188 antibody (Figures 1C,E,H,J). In contrast, the
22C11 antibody did not show specific staining (Figures 1K–O).
To quantify protein levels and to corroborate our
immunofluorescence data, we performed double-fluorescence
western blot analysis using whole hippocampal homogenates
as well as laser microdissected tissue samples of CA1 pcl and
DG gcl. Holo-APP (∼95–100 kDa) was recognized by all three
APP antibodies in wild type but not in APP deficient tissue
samples (Figure 2). CT20 and 22C11 demonstrated additional
fragments of smaller size in both genotypes (Figure 2). The
Y188 antibody appeared to be the most specific of the three,
which was in line with our recent western blot results using this
antibody indicating that it primarily detects full-length APP
whereas the relative abundance of C-terminal stubs that are
detected by this antibody is much lower (Fol et al., 2016). Based
on these results, we chose Y188 to quantitatively determine
APP in laser microdissected samples of hippocampal subregions
(Figure 3).
In line with our immunofluorescence labeling, quantitative
western blot analysis of microdissected tissue revealed a
significantly higher APP protein level (approximately 1.7 fold) in
the pcl of CA1 compared to the gcl of the DG (Figure 3). These
FIGURE 1 | Specificity of amyloid precursor protein (APP) antibodies
tested on hippocampal sections of adult wild type and APP deficient
mice. (A) Immunofluorescence of the dorsal hippocampus of wild type (+/+)
mice using the Y188 antibody. The dentate gyrus (DG) shows only a weak
signal, whereas a more intense labeling is seen in Ammon’s horn (CA1–3).
(B,C) Immunofluorescence is detectable in the granule cell layer (gcl) and
molecular layer (ml) of the DG in wild type but not in brain sections of APP
deficient mice using the Y188 antibody. (D,E) Principal cell layer (pcl) of
CA1 shows a strong signal in wild type mice. Some immunofluorescence is
also seen in stratum radiatum (sr). In contrast, staining is absent in
APP-deficient hippocampal tissue. (F–J) Immunofluorescence of the
hippocampus of wild type and APP deficient mice using the CT20 antibody.
(F,G,I) Similar to the results with Y188 a stronger signal can be seen in
Ammon’s horn (CA1–3) of wild type mice compared to the DG.
(H,J) Background staining is slightly higher in APP-deficient tissue sections
compared to the background seen with the Y188 antibody (in C,E).
(K–O) Immunostaining using the 22C11 antibody shows similar staining in wild
type and APP-deficient tissue, suggesting that this antibody is not sufficiently
specific to identify APP in tissue sections (K), DG (L,M) and CA1 (N,O).
Scale bars: (K) 500 µm; (M,O) 25 µm.
data confirmed our initial impression that APP is differentially
expressed in these two hippocampal subregions.
APP is Predominantly Expressed by
Neurons in the Adult Mouse Hippocampus
To elucidate, which hippocampal cell types produce relevant
amounts of APP protein, we performed confocal double-
immunofluorescence analysis using Y188 in combination with
the neuron-specific marker NeuN (neuronal nuclear antigen)
or the astrocytic marker GFAP (glial fibrillary acidic protein;
Figure 4). We performed this staining since earlier publications,
which were in part performed in tissue cultures, had also
suggested an astroglial expression of APP (Golde et al., 1990;
Haass et al., 1991; LeBlanc et al., 1991). In our preparations,
we found that APP is predominantly expressed by hippocampal
neurons (Figures 4A–D). In contrast, we did not detect an
astroglial APP expression (Figures 4F–J). Of note, APP-positive
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FIGURE 2 | Western blot analysis of APP protein in adult mouse
hippocampus. Western blotting of the three antibodies used for detecting
APP, i.e., Y188, CT20 and 22C11, shows the typical set of bands
corresponding to holoAPP (hAPP) protein (∼95–100 kDa) in hippocampal
homogenates of adult wild type (APP+/+) mice but not in APP deficient
(APP−/−) tissue. Additional bands of smaller sizes seen with both CT20 and
22C11 antibodies are not specific for APP, as they are also seen in the APP
KO control. GAPDH (∼35–38 kDa) was used as loading control. L: Ladder
(Precision Plus Protein™ Dual Color Standards, BIO-RAD).
neurons were not only found in the principal cell layers of the
hippocampus, i.e., in pcl of Ammon’s horn and, to some weaker
extent, in the dentate gcl, but also in adjacent layers, e.g., hilus,
stratum radiatum (sr) or stratum lacunosum-moleculare (slm;
Figures 4A,C).
To also identify App mRNA-expressing cells in the
hippocampus, we next performed non-radioactive ISH using a
digoxygenin-labeled riboprobe. This probe detects an mRNA
sequence corresponding to the juxtamembrane region of APP,
which is present in all major APP isoforms, i.e., APP-770,
APP-751 and APP-695, but not conserved in the related
APLPs. Strongly App mRNA-expressing cells were detected
in the pcl of Ammon’s horn and in the hilus of the DG,
whereas only a comparatively weak ISH signal was observed
in the dentate gcl (Figures 5A,C). Outside the principal cell
layers, only few App mRNA-expressing cells could be found
in the adjacent layers, e.g., sr or slm (Figure 5D), which is
an expression pattern that corresponds to the expression of
APP by interneurons (Wang et al., 2014) but not by astroglia.
Hippocampal tissue of APP deficient mice served as negative
control and was stained using the same anti-sense riboprobe.
This experiment revealed only weak non-specific background
(Figure 5B).
Together, the results obtained by ISH, immunofluorescence
and western blot analysis suggest that AppmRNA as well as APP
protein are predominantly expressed by principal neurons but
not by astroglial cells in the adult mouse hippocampus.
Quantitative Analysis of App mRNA
Expression in Hippocampal Subregions
By using qPCR in combination with LMD, we aimed to compare
App mRNA expression levels in the pcl of CA1 compared
to the gcl of the DG. For this purpose, only high quality
FIGURE 3 | Western blot analysis of APP protein in microdissected
hippocampal subregions of adult mouse. (A,B) Laser microdissection
(LMD) of hippocampal subregions, i.e., CA1 pyramidal cell layer (pcl) and the
gcl of the DG. (C) Western blotting using the Y188 antibody shows a specific
signal corresponding to APP protein (∼95–100 kDa) in DG gcl and CA1 pcl.
GAPDH (∼35–38 kDa) was used as loading control. (D) Quantitative western
blot analysis reveals higher APP protein levels (∼1.7-fold) in CA1 pcl relative to
DG gcl samples. Data (N = 3 mice, n = 3 for each region) were tested for
statistical significance using t-test (two-tailed), ∗p ≤ 0.05. Values are
represented as mean ± standard deviations (SD).
RNA samples (RIN-values: ∼9) of laser microdissected cell
layers were used (Figures 6A–C). To more reliably analyze
possible differences in gene expression, we first validated a
panel of suitable reference genes (see Table 1 for details)
for both hippocampal subregions in order to achieve robust
qPCR data. Two established and widely accepted algorithms,
i.e., geNorm and NormFinder, were used for the expression
stability ranking of reference genes for CA1 and DG (Table 2).
As determined by pairwise variation using geNorm and
accumulated SD analysis according to NormFinder, the
most stable reference genes as well as the minimal number
necessary for accurate normalization were determined
(Figures 6D,E,G,H). Of note, both algorithms showed a
comparable ranking for all of the candidate reference genes
tested (Table 2; Figures 6D,G).
Based on this data set, we used a normalization index
out of the two most stable reference genes as well as the
best combination of suitable genes, i.e., Gapdh and Sdha for
geNorm, and Gapdh and Pgk1 for NormFinder, respectively.
For App gene expression analysis, two different qPCR assays
specific for all major App isoforms were selected, which
detected almost identical gene expression levels. Using this
strategy, we determined a significantly higher expression
of App mRNA (1.5- to 1.7-fold) in CA1 pyramidal cells
compared to granule cells of the DG using either of the
reference gene indices for accurate normalization of qPCR data
(Figures 6F,I).
DISCUSSION
In the present study, we analyzed the expression of APP at
the protein and mRNA level in the gcl and CA1 pcl of the
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FIGURE 4 | APP immunoreactivity is predominantly detected in
neurons of the adult mouse hippocampus. (A–E) Confocal
double-immunofluorescence staining for APP using Y188 (red) in combination
with the neuron-specific marker NeuN (green) in wild type brain sections
shows a strong neuronal APP expression in the pcl of area CA1 compared to
the DG gcl. of note, Y188 and NeuN double positive cells were also found in
adjacent layers (e.g., hilus and stratum radiatum, sr).
(F–J) Double-immunofluorescence staining for APP (Y188, red) and the
astrocytic marker GFAP (green) revealed no APP expression by this glial cell
population in the adult mouse hippocampus. DRAQ5 was used to visualize
cell nuclei (blue). Scale bar: (A,F) 200 µm; (B,G) 25 µm; (E,J) 12.5 µm.
adult mouse hippocampus using confocal immunofluorescence,
ISH and LMD in combination with qPCR or western blot
analysis. Our main findings can be summarized as follows:
full-length APP is expressed by neurons under physiological
conditions. APP expression is ∼1.7× stronger at both mRNA
and protein level in CA1 pyramidal cells compared to
dentate granule cells. We propose that these differences
in basal APP expression may contribute to the regional
differences in APP function we reported in earlier studies
using APP−/− animals (Ring et al., 2007; Jedlicka et al.,
2012).
Endogenous Full-Length APP Levels in the
Mouse Hippocampus—Methodological
Considerations
Quantification of endogenous APP levels in the brain is
confounded by the fact that some commercially available
antibodies recognize not only full-length APP but also APP
cleavage products and/or other protein fragments (Guo et al.,
2012). In addition, antibodies may cross-react with the highly
homologous APLPs, which further limits antibody specificity
(Slunt et al., 1994). Thus, we ensured using tissue of APP−/−
mice that the antibodies we used for immunohistochemistry
and western blot analysis in this study are highly specific
and can be employed to detect holo-APP in the mouse
FIGURE 5 | Non-radioactive in situ hybridization (ISH) for App mRNA in
the adult mouse hippocampus. (A) ISH using a digoxygenin-labeled
anti-sense riboprobe demonstrates App mRNA expression in the
hippocampus of an adult wild type (APP+/+) mouse. Principal layers of
Ammon’s horn show a strong expression for App mRNA. (B) Hippocampal
tissue of APP deficient (APP−/−) mice served as negative control and was
stained with the same anti-sense riboprobe. This showed only non-specific
signals. (C) App mRNA expression is strong in the pcl of area CA3 and in the
dentate hilus (h). In contrast, the mRNA-signal is much weaker in the gcl of the
DG. Molecular layer (ml). (D) App mRNA is strongly expressed in pcl of CA1. In
addition, a small number of App mRNA—positive cells are found in the
adjacent layers, e.g., stratum oriens (so), stratum radiatum (sr), or stratum
lacunosum-moleculare (slm). Scale bars: (A) 100 µm; (C,D) 50 µm.
hippocampus with high reliability. Furthermore, since APP is
expressed in different isoforms in the nervous system and the
brain (Kang and Müller-Hill, 1990; Sisodia et al., 1993), we
designed probes for ISH and primers for qPCR which detect
the three major isoforms of APP. Choice of these tools for our
quantitative analysis make us confident that we predominantly
measured total full-length APP mRNA and protein in our
study.
Furthermore, since we were specifically interested in the
neuronal expression of APP in these two regions and since our
immunohistochemistry revealed a neuron-specific expression
pattern of APP in the hippocampus (see below) we used
LMD to selectively harvest the neuronal cell layers, i.e., the
gcl of the DG and the CA1 pcl, respectively. This approach
makes our quantification quite specific for granule cells and
CA1 pyramidal cells, since the number of principal cells by
far exceeds the number of cells of other cell types in these
layers. Thus, we are confident that we here report robust and
reliable data on the relative expression of APP mRNA and
protein in the principal neurons of two major subfields of the
hippocampus.
Full-Length APP is Expressed by Neurons
in the Mouse Hippocampus
In the adult rodent CNS, three major APP isoforms encoded by
alternatively spliced transcripts have been described. In line with
Guo et al. (2012), our data indicate that in tissue of intact and
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FIGURE 6 | Quantitative App mRNA expression in hippocampal subregions. (A,B) LMD of hippocampal subregions, i.e., CA1 pcl and gcl of the DG.
Representative section of the dorsal hippocampus (coronal plane, cresyl violet staining) before (A) and after (B) LMD is shown. Scale bar: 250 µm. (C) RNA integrity
analysis of total RNA isolated from the dissected gcl (red) and from pcl (blue) demonstrating highly intact RNA (RIN-values: ∼9; Agilent 2100 Bioanalyzer).
(D,E) Average expression stability values (M) and evaluation of the optimum number of candidate reference genes for CA1 pcl and for DG gcl according to geNorm
software. Pairwise variation (V) of candidate reference genes indicates that the use of the two most stable genes is sufficient to obtain an accurate normalization
index for quantitative PCR (qPCR) analysis. (F) A significantly higher gene expression for App (1.5- to 1.7-fold) was detected in CA1 pcl relative to DG gcl using two
different App-specific TaqMan assays (A: Mm_01344172_m1, B: Mm_00431830_m1) after normalization to a reference gene index calculated by geNorm.
(G,H) Gene expression stability values (S) and accumulated SD analysis using NormFinder. The minimal number of reference genes required for effective
normalization is highlighted. (I) Comparable to the results obtained by geNorm algorithm, a significantly higher App expression (1.6- to 1.7-fold) was detected in
CA1 pcl relative to DG gcl after normalization to the reference gene index estimated by NormFinder. Data (N = 5–6 mice) were tested for statistical significance using
one-way ANOVA followed by Bonferroni post hoc test to correct for multiple comparisons, ∗p ≤ 0.05.
otherwise untreated mouse brain endogenous APP is expressed
selectively by neurons but not astroglia: neither immunostaining
with the APP-specific antibody Y188 nor ISH with App-specific
riboprobes revealed a glial expression pattern. Similarly, double-
labeling for neuronal and astroglial markers revealed a highly
selective neuronal expression. In culture, however, previous
studies reported that both astrocytes and microglia express APP
(Haass et al., 1991; LeBlanc et al., 1991; Forloni et al., 1992;
Mönning et al., 1995) and during aging Aß production has also
been reported from non-neuronal sources in transgenic APP
overexpressing mice. Thus, the possibility exists that glial cells
express APP under reactive conditions in vivo. This issue was
previously addressed by Guo et al. (2012), who used a traumatic
brain injury model and an AD mouse model and failed to
detect APP-positive astrocytes using APP-specific antibodies.
They concluded that in vivo APP levels in astrocytes may be
too low for detection even under reactive conditions (Guo et al.,
2012). In our own investigations, in which we used entorhinal
cortex lesions (Lynch et al., 1978; Steward, 1994; Deller and
Frotscher, 1997) to denervate the DG, we also failed to see an
Frontiers in Molecular Neuroscience | www.frontiersin.org 7 November 2016 | Volume 9 | Article 134
Del Turco et al. APP Expression in the Mouse Hippocampus
TABLE 1 | Details of qPCR assays used in this study.
Gene symbol Gene name Accession number TaqMan assay number Exon Location Amplicon
size (bp)
App amyloid beta (A4) precursor protein NM_001198823.1 Mm01344172_m1 17–18 2358 111
NM_001198824.1 16–17 2301
NM_001198825.1 15–16 2247
NM_001198826.1 16–17 2304
NM_007471.3 15–16 2133
App amyloid beta (A4) precursor protein NM_001198823.1 Mm00431830_m1 14–15 2064 82
NM_001198824.1 13–14 2007
NM_007471.3 12–13 1839
Gapdh glyceraldehyde-3-phosphate
dehydrogenase
NM_008084.3 Mm99999915_g1 2–3 265 107
NM_001289726.1 2–3 117
Pgk1 phosphoglycerate kinase 1 NM_008828.3 Mm00435617_m1 5–6 675 137
Sdha succinate dehydrogenase complex,
subunit A, flavoprotein (Fp)
NM_023281.1 Mm01352366_m1 6–7 804 82
Gene symbol Gene name Accession number Primers (forward, reverse) Exon Location Amplicon
size (bp)
Actb actin, beta NM_007393.3 GAAGATCAAGATCATTGCTCCT
TGGAAGGTGGACAGTGAG
5–6 1054–1137 84
Alas1 aminolevulinic acid synthase 1 NM_020559 CGATGCCCATTCTTATCC
TTGAGCATAGAACAACAGAG
2 210–284 75
B2m beta-2
microglobulin
NM_009735 CCTCTGTACTTCTCATTACTTG
GCCTCTTTGCTTTACCAA
4 670–761 92
Hprt hypoxanthine guanine phosphoribosyl
transferase
NM_013556.2 GTGATTAGCGATGATGAAC
TTCAGTCCTGTCCATAATC
2–3 988–1065 117
Gapdh glyceraldehyde-3-phosphate
dehydrogenase
NM_008084.2 ACAATGAATACGGCTACAG
GGTCCAGGGTTTCTTACT
7 171–287 78
Pgk1 phosphoglycerate kinase 1 NM_008828.2 CGTGATGAGGGTGGACTT
TGGAACAGCAGCCTTGAT
1–3 184–262 79
Ppia peptidylprolyl isomerase A NM_008907.1 CAAGACTGAATGGCTGGAT
ATGGCTTCCACAATGTTCA
4–5 392–466 75
Rpl13a ribosomal protein L13A NM_009438.5 TCCACCCTATGACAAGAA
GTAAGCAAACTTTCTGGTAG
5–7 348–432 85
Sdha succinate dehydrogenase complex,
subunit A, flavoprotein (Fp)
NM_023281.1 CAAGACTGGCAAGGTTAC
ATCAGTAGGAGCGGATAG
14–15 1928–2028 101
Tfrc transferrin receptor NM_011638 CTATATCGGAGACAGTGAT
GCTACAGGAAGTTAGGAA
19 307–433 148
increase in App mRNA in the denervated outer molecular layer
(Del Turco et al., 2014). In this layer, reactive glia are particularly
abundant (Deller et al., 2000, 2007; Del Turco et al., 2014).
Although these two reports cannot rule out the possibility that
under some other conditions APP is expressed in vivo by glial
cells, they certainly suggest that glial APP is not the primary
source of APP in the intact or injured brain.
Endogenous Neuronal App mRNA Levels
are Tightly Controlled
It has been pointed out by others that App is regulated very
much like a housekeeping gene (Dawkins and Small, 2014).
The fact that the App promoter lacks TATA and CAAT boxes
but contains sites for several transcription factors regulating
the expression of proteins associated with cell proliferation and
differentiation suggests that App mRNA levels are primarily
regulated during development (Izumi et al., 1992; Clarris et al.,
1995; for review see Dawkins and Small, 2014). In the adult brain
AppmRNA levels may bemuchmore tightly controlled to supply
neural tissue with a constant level of APP protein for further
processing.
However, a certain degree of transcriptional regulation has
been reported for APP and App mRNA in adult neurons
following brain injury (Murakami et al., 1998; Van Den Heuvel
et al., 1999, 2007; Itoh et al., 2009). This appears to be of
relevance, since head trauma is considered a risk factor for
AD (e.g., Mortimer et al., 1991; Szczygielski et al., 2005).
Concerning this lesion-induced regulation, the experimental
literature is somewhat controversial (Szczygielski et al., 2005). By
hindsight this is not surprising since many different antibodies
and probes were used and some of them may not have been
tested for specificity. In our own investigations using the
entorhinal cortex lesion model we initially failed to observe
an increase in App mRNA using screening methods. Only
after using the sensitive LMD/qPCR approach (Burbach et al.,
2003), which made it possible to measure App mRNA within
microdissected cell and fiber layers did we detect a ∼1.3-
fold increase of App mRNA in denervated granule cells at
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TABLE 2 | Ranking of candidate reference genes by geNorm and
NormFinder.
CA1 (pcl) + DG (gcl)
Rank geNorm (M) NormFinder (S)
1 Gapdh + Sdha 0.111 Gapdh 0.030
2 Pgk1 0.043
3 Pgk1 0.133 Sdha 0.067
4 Actb 0.160 Actb 0.077
5 Alas1 0.185 Alas1 0.085
6 Ppia 0.207 Ppia 0.131
7 Tfrc 0.230 Tfrc 0.138
8 Hprt 0.251 Hprt 0.145
9 B2m 0.277 B2m 0.199
10 Rpl13a 0.319 Rpl13a 0.233
Expression stability values of candidate reference genes for CA1 pyramidal cell
layer (pcl) and for granule cell layer (gcl) of the dentate gyrus (DG) calculated by
geNorm (M-values) and NormFinder (S-values) algorithms.
7 days post lesion (Del Turco et al., 2014). We conclude that
neuronal App expression is tightly regulated and even under
extreme conditions, e.g., brain injury, App gene expression
changes range between 1- to 2-fold. If translated 1:1 into
protein, as our present study suggests, such an increase in App
mRNA may, however, be biologically and pathophysiologically
relevant.
Finally, it should be kept in mind that transcriptional
regulation of App is only one regulatory step under physiological
and pathophysiological conditions, likely limiting the
amount of full-length APP protein available for downstream
processing. Post-transcriptional regulation by miRNAs has
also been recently described (Schonrock et al., 2012). Most
importantly, however, the amount, availability and activity
of the secretases eventually decide the ‘‘biological fate’’ of
the full-length protein by liberating its biologically active
fragments. In contrast to the levels of App mRNA, which
appear to be tightly controlled and provide neurons with
a basal supply of APP, the activity and/or expression of
secretases is regulated by neuronal activity and many other
conditions, which have been reviewed elsewhere (Endres and
Fahrenholz, 2012; Sun et al., 2012; Vassar et al., 2014; Vincent,
2016).
Basal Expression of APP is Higher in
CA1 Pyramidal Neurons Compared to
Dentate Granule Cells
ISH against endogenous App mRNA revealed a weaker labeling
of dentate granule cells compared to the pyramidal cells of
Ammon’s horn. This made us wonder whether this reflected
a true regional difference between the DG and the other
hippocampal subfields. Since non-radioactive ISH cannot be
reliably used for quantitative analysis, we quantified AppmRNA
using qPCR. Using LMD, the principal cell layers were harvested,
which reduced dilution effects. The careful selection of reference
genes using current recommendations for qPCR (Vandesompele
et al., 2002; Andersen et al., 2004) ensured a very robust reference
for the subregional comparison. In sum, this revealed a 1.5- to
1.7-fold difference in App mRNA expression between the DG
and area CA1. The difference in App mRNA level translates
into protein, since we used the same LMD approach to obtain
the tissue for western blot analysis and found a comparable
difference for APP protein, i.e., ∼1.7-fold more protein in area
CA1 compared to the DG.
Regional Differences in APP Expression
May Contribute to Regional Differences in
Synaptic Plasticity
The physiological role of APP has been investigated in
the hippocampus using APP−/− mice. This loss-of-function
approach revealed a robust role for APP in synaptic plasticity
at the CA3-CA1 synapse (Dawson et al., 1999; Ring et al.,
2007). Animals lacking APP showed an impaired LTP,
which went hand-in-hand with memory dysfunctions. In
contrast, using similar stimulation protocols for synaptic
strengthening, the same line of APP−/− mice did not show
an LTP-defect at the EC-GC synapse in vivo (Jedlicka
et al., 2012). This was a somewhat surprising result and
we suggest—based on the data reported in this article—that
differences in APP expression level between the two regions
might contribute to the functional differences seen in our
recordings.
How could different APP levels in neurons contribute to
differences in synaptic function? Although the physiological role
of APP is not yet fully understood several recent publications
have suggested important functions for APP and its cleavage
products at central synapses. With regard to full-length APP,
it has been shown that it can act as a cell-adhesion molecule
in trans, i.e., linking pre- and postsynapse, thus affecting the
stability of synapses (Soba et al., 2005; Stahl et al., 2014). On
the presynaptic side, APP regulates the abundance of synaptic
vesicle proteins andmay impact on synaptic transmission (Laßek
et al., 2013, 2014, 2016a,b; Fanutza et al., 2015). This presynaptic
effect is in line with our own findings, which indicate that lack
of APP causes presynaptic changes at the EC-GC (Jedlicka et al.,
2012) as well as the CA3-CA1 synapses (Hick et al., 2015).
On the postsynaptic side, sAPPα, which is generated from APP
by α-secretase cleavage, appears to be required for synaptic
strengthening. Experiments using sAPPα-binding antibodies and
recombinant sAPPα (Turner et al., 2003; Taylor et al., 2008) as
well as our own approaches using mouse genetics (Ring et al.,
2007; Hick et al., 2015) revealed an essential function of this
fragment in Hebbian-plasticity at both synapses. Most likely,
the APP effect on synaptic plasticity is caused by an increased
delivery of NMDAR to synapses (Cousins et al., 2009; Hoe et al.,
2009), resulting in increased NMDAR currents (Taylor et al.,
2008). In conclusion, APP and its cleavage products influence
synaptic function at both pre- and postsynapse. It is thus highly
likely that regional differences in APP levels could impact
on the effect size experimenters can observe using APP-KO
mice.
Unraveling and understanding the role of APP at central
synapses is non-trivial and may ultimately require synapse-
specific answers. In addition to the above discussed differences
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in APP levels, differences in APP processing and thus the
abundance of specific fragments such as sAPPα between brain
regions may also play an important role. Likewise, regional
differences in the expression of APP-like proteins, i.e., APLP1 or
APLP2, which can partially compensate for a loss of APP
could affect the interpretation of loss-of-function experiments
(von Koch et al., 1997; Heber et al., 2000; Weyer et al.,
2011; Hick et al., 2015; Vnencak et al., 2015). Regardless of
all these considerations, however, APP can only play a role
in synaptic plasticity of a synapse if it is present. If not,
other factors will predominate. Thus, we feel confident to
conclude that APP plays a greater role for synaptic plasticity
in area CA1 compared to the DG in mice. This finding,
which implies that some effects of APP are region-specific,
may be of relevance for future studies on APP and may also
affect the design and analysis of APP-related animal models
of AD.
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